DelveInsight’s, “Brain Metastases Pipeline Insight, 2023,” report provides comprehensive insights about 50+ Brain Metastases companies and 50+ pipeline drugs in the Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including Brain Metastases clinical trials and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Brain Metastases Pipeline Insight Report
Explore more about the latest breakthroughs of the Brain Metastases Treatment Landscape @ Brain Metastases Pipeline Outlook
Brain Metastases Overview
Brain metastases are the most common intracranial tumor in adults and may affect up to 200,000 patients per year. The three most common primary malignancies that metastasize to the brain are lung, breast, and melanoma. Additional cancers with brain metastases include renal cell, colorectal cancer, and gynecologic cancers. Signs and symptoms caused by brain metastases can vary based on the location, size and rate of growth of the metastatic tumors. About one third of patients with another type of cancer will develop one or more metastatic brain tumors. The risk for metastatic brain tumors begins to increase after age 45 and is highest in those over 65. Signs and symptoms of brain metastases include: Headache, sometimes with vomiting or nausea, mental changes, such as increasing memory problems, Seizures, and Weakness or numbness on one side of the body. Brain metastasis diagnosis is suspected through thorough physical examination and history. Brain metastasis can be diagnosed utilizing the following tests: Computed Axial Tomography, Magnetic Resonance Imaging and others. Treatment varies with the size and type of the tumor, the primary site of the malignancy, its extent both locally and in the rest of the body (staging), the general health of the individual and presence of other significant medical problems.
Recent Developmental Activities in the Brain Metastases Treatment Landscape
Discover more about the Brain Metastases Emerging Therapies and Companies report @ Brain Metastases Treatment Landscape
Brain Metastases Emerging Drugs Profile
HBI-8000: HUYA Bioscience International
HBI-8000 is a Class I selective oral HDACi with immunomodulatory effects including enhanced cell-mediated toxicity, enhanced tumor infiltration by cytotoxic T-cells and reduced tumor infiltration by T-regulatory cells. Phase III clinical trials are being evaluated for the treatment of patients with progressive brain metastasis.
ANG1005: Angiochem
ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem’s technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain. Currently, the drug is being evaluated in Phase III stage of Clinical trial evaluation for the treatment of Brain metastases.
AZD3759: Alpha BioPharma
Alpha Bio is conducting multi-center Phase II/III clinical study of AZD3759, a TKI for EGFR mutation-positive cases of non-small cell lung cancer with CNS metastasis particularly brain metastasis.
Brain Metastases Therapeutics Assessment
There are approx. 50+ key Brain Metastases companies which are developing the therapies for Brain metastases. The companies which have their Brain metastases drug candidates in the most advanced stage, i.e. phase III include, Betta Pharmaceuticals.
Learn more about the Brain Metastases Emerging Therapies @ Brain Metastases Ongoing Clinical Trials Analysis
Scope of the Brain Metastases Pipeline Report
Table of Content
For further information on the Brain Metastases Pipeline Therapeutics, reach out @ Brain Metastases Market Drivers and Barriers
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/